ArticleGene therapy2010
IL-10 delivery by AAV5 vector attenuates inflammation in mice with Pseudomonas pneumonia.
Article in Gene therapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 35 citations in OpenAlex.
- Gene Therapy for Acute Respiratory Distress Syndrome.Frontiers in physiology · 2021Review
- Acute lung injury induced by whole gastric fluid: hepatic acute phase response contributes to increase lung antiprotease protection.Respiratory research · 2016Article
- Pediatric Acute Respiratory Distress Syndrome: Fibrosis versus Repair.Frontiers in pediatrics · 2016Review
- Immunological priming requires regulatory T cells and IL-10-producing macrophages to accelerate resolution from severe lung inflammation.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- Acute respiratory distress syndrome: new definition, current and future therapeutic options.Journal of thoracic disease · 2013Article
- Inhibiting periapical lesions through AAV-RNAi silencing of cathepsin K.Journal of dental research · 2013Article
- Article
- Absence of the cystic fibrosis transmembrane regulator (Cftr) from myeloid-derived cells slows resolution of inflammation and infection.Journal of leukocyte biology · 2012Article
- Adeno-associated virus mediated delivery of Tregitope 167 ameliorates experimental colitis.World journal of gastroenterology · 2012Article
- Intranasal vaccination with AAV5 and 9 vectors against human papillomavirus type 16 in rhesus macaques.Human gene therapy · 2012Article
- Gene and cell therapy based treatment strategies for inflammatory bowel diseases.World journal of gastrointestinal pathophysiology · 2011Article
- Intranasal administration of adeno-associated virus type 12 (AAV12) leads to transduction of the nasal epithelia and can initiate transgene-specific immune response.Molecular therapy : the journal of the American Society of Gene Therapy · 2011Article
- Gene therapy for ALI/ARDS.Critical care clinics · 2011Review
- Development and validation of a multiplex microsphere-based assay for detection of domestic cat (Felis catus) cytokines.Clinical and vaccine immunology : CVI · 2011Article
- Acute lung injury: how macrophages orchestrate resolution of inflammation and tissue repair.Frontiers in immunology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Lung infections with Pseudomonas aeruginosa and other pathogens in cystic fibrosis (CF) cause progressive airway obstruction and tissue damage, the predominant cause of morbidity and mortality in CF. We investigated whether a recombinant adeno-associated virus type 5 (AAV5) vector expressing murine interleukin (IL)-10 (AAV5.Cbeta-mIL-10), a regulatory/anti-inflammatory cytokine, could decrease airway inflammation in IL-10 knockout mice chronically infected with mucoid P. aeruginosa. Mice that received AAV5.Cbeta-mIL10 through intratracheal inoculation produced IL-10 at an average of 25 000 pg/ml in the epithelial lining fluid (ELF) and 12 000 pg/g-lung tissue 6 weeks post-vector delivery, significantly higher levels than in placebo-treated mice. At 3 days post-infection, proinflammatory cytokines (IL-1beta, tumor necrosis factor (TNF)-alpha, macrophage inhibitory protein (MIP)-1alpha and (KC) in the ELF and lung homogenate were decreased (1-9 folds) in the AAV5.Cbeta-mIL10-treated mice accompanied by less pronounced and more localized neutrophil infiltration in lung sections, when compared with placebo-treated mice. These results suggest that AAV5.Cbeta-mIL10 induces IL-10 levels in the lungs mediating a significant anti-inflammatory response and making AAV-IL-10 gene transfer a potentially useful therapy in the treatment of CF lung disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.